The Performance of 18F-FAPI PET/CT in Patients With Various Types of Cancer
Overview
- Phase
- Not Applicable
- Intervention
- 18F-FAPI
- Conditions
- Cancer
- Sponsor
- Jilin University
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Diagnostic accuracy
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
To evaluate the potential usefulness of 18F-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.
Detailed Description
Subjects with various types of cancer underwent 18F-FAPI PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). Using histopathology and follow-up as gold standard, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FAPI PET/CT were calculated.
Investigators
Ji Bin
Doctor
Jilin University
Eligibility Criteria
Inclusion Criteria
- •patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
- •patients who had scheduled 18F-FAPI PET/CT scan; (iv)
- •patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria
- •patients with non-malignant lesions;
- •patients with pregnancy;
- •the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Arms & Interventions
18F-FAPI
Experimental: Experimental: 18F-FAPI Each subject receive a single intravenous injection of 18F-FAPI, and undergo PET/CT imaging within the specificed time.
Intervention: 18F-FAPI
Outcomes
Primary Outcomes
Diagnostic accuracy
Time Frame: 1 year
The sensitivity, specificity and accuracy of 18F-FAPI PET/CT were calculated.